Heterogeneity in statin responses explained by variation in the human gut microbiome

Prior work has indicated that stain therapy impacts gut microbiome composition and that gut bacteria can metabolize statins, but the clinical implications of these interactions remain unknown. Wilmanski et al. identify robust associations between microbiome composition and on-target and adverse responses to statins, which could prove useful in drug personalization.

Video: Tomasz Wilmanski, PhD
Institute for Systems Biology, Seattle, WA, USA